These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26833071)

  • 1. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
    Adusumilli S; Haydel SE
    BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and ion-exchanged illite clays reduce bacterial burden and inflammation in cutaneous meticillin-resistant Staphylococcus aureus infections in mice.
    Otto CC; Kilbourne J; Haydel SE
    J Med Microbiol; 2016 Jan; 65(1):19-27. PubMed ID: 26508716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection.
    Tian RB; Asmar S; Napez C; Lépidi H; Drancourt M
    Int J Antimicrob Agents; 2017 Mar; 49(3):290-295. PubMed ID: 28131607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
    Fukano H; Nakanaga K; Goto M; Yoshida M; Ishii N; Hoshino Y
    PLoS One; 2022; 17(10):e0274742. PubMed ID: 36201529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans.
    Yemoa A; Gbenou J; Affolabi D; Moudachirou M; Bigot A; Anagonou S; Portaels F; Quetin-Leclercq J; Martin A
    Planta Med; 2011 Apr; 77(6):641-6. PubMed ID: 21240839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
    Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
    Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL
    PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of avermectins against Mycobacterium ulcerans.
    Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.
    Scherr N; Pluschke G; Thompson CJ; Ramón-García S
    PLoS Negl Trop Dis; 2015 Aug; 9(8):e0003996. PubMed ID: 26270480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.